Collaboration will explore experimental treatment IMM-101 in combination with other therapies in advanced cancers
News
Cosentyx wins EU approval for first-line paediatric psoriasis
Low-dose and high-dose Cosentyx is effective in rapidly improving skin symptoms and quality of life
Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study
Subcutaneous formulation of Darzalex in combination with pomalidomide and dexamethasone meets primary endpoint
Sanofi, GSK in advanced discussions with EU for COVID-19 vaccine
Supply deal could include up to 300 million doses of vaccine
US expands scope of Janssen’s Stelara
The new approval cover paediatric patients with plaque psoriasis
UK firm starts research on skin patch for COVID vaccines
The patch will be tested to deliver a vaccine dose via the skin, as well as achieve a simple and secure disposal process to enable at-home use.
MHRA OKs Celltrion’s Phase I trial of COVID drug
The trial will enrol patients with mild symptoms of SARS-CoV-2 infection to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59
EU regulators approve Novartis’ breast cancer combo
Piqray in combination with fulvestrant is the first treatment for tumours with a PIK3CA mutation
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Nirsevimab shows promise for long-term RSV protection
The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
GSK sees dip in second-quarter sales
Sales decline in the second quarter reflects expected disruption from COVID-19
NICE rejects NHS funding for Kyowa Kirin’s Poteligeo
NICE is not recommending NHS funding for Kyowa Kirin’s Poteligeo (mogamulizumab) as a treatment for mycosis fungoides or Sézary syndrome for adults who have had at least one previous systemic treatment.
NHS People Plan to address new pandemic challenges
The plan sets out a new a new recruitment, retention and support package
EC approves subcutaneous version of Remsima
The SC formulation can be administered by patients themselves, reducing treatment time to approximately two-five minutes
New research to investigate higher COVID-19 risk among BAME groups
It is hoped that the six new projects, which total £4.3 million worth of funding, will further understanding on the link between ethnicity and susceptibility to the virus
